Immunohistochemical analysis of carcinomatous and sarcomatous components in the uterine carcinosarcoma: A case report

Pathology Research and Practice

Volumn 204, Issue 3, 2008, Pages 203-207

  Semczuk, Andrzej ^a   Skomra, Danuta ^a   Chyzyńska, Monika ^a   Szewczuk, Wiktor ^a   Olcha, Piotr ^a   Korobowicz, Elzbieta ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Immunohistochemistry; MIB 1 PI; Uterine carcinosarcoma

Indexed keywords

ANDROGEN RECEPTOR; BETA CATENIN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOOXYGENASE 2; CYTOKERATIN; DESMIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; RETINOBLASTOMA 1 PROTEIN; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; VIMENTIN;

ADULT; ARTICLE; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; CARCINOSARCOMA; CASE REPORT; CLINICAL FEATURE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IRRADIATION; LYMPH NODE DISSECTION; POSTOPERATIVE PERIOD; RADIATION DOSE; SALPINGOOOPHORECTOMY; TREATMENT RESPONSE; UTERUS CARCINOMA;

BETA CATENIN; CARCINOSARCOMA; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLOOXYGENASE 2; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-BCL-2; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, PROGESTERONE; RETINOBLASTOMA PROTEIN; TUMOR MARKERS, BIOLOGICAL; UTERINE NEOPLASMS; VIMENTIN;

EID: 39149132788     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2007.11.009     Document Type: Article

References (28)

1. Ali S., and Wells M. Mixed Mullerian tumors of the uterine corpus: a review. Int. J. Gynecol. Cancer 3 (1993) 1-11
2. Ansink A.C., Cross P.A., Scorer P., de Barros Lopes A., and Monaghan J.M. The hormonal receptor status of uterine carcinosarcomas (mixed Mullerian tumours): an immunohistochemical study. J. Clin. Pathol. 50 (1997) 328-331
3. Cimbaluk D., Rotmensch J., Scudiere J., Gown A., and Bitterman P. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. Gynecol. Oncol. 105 (2007) 138-144
4. Ferrandina G., Zannoni G.F., Martinelli E., Vellone V., Prisco M.G., and Scambia G. Endometrial carcinoma recurring as carcinosarcoma: report of two cases. Pathol. Res. Pract. 203 (2007) 677-681
5. Gagne E., Tetu B., Blondeau L., Raymond P.E., and Blais R. Morphologic prognostic factors of malignant mixed Mullerian tumor of the uterus: a clinicopathologic study of 58 cases. Mod. Pathol. 2 (1989) 433-438
6. Grayson W., Taylor L.F., and Cooper K. Carcinosarcoma of the uterine cervix: a report of eight cases with immunohistochemical analysis and evaluation of human papillomavirus status. Am. J. Surg. Pathol. 25 (2001) 338-347
7. Hacker N.F. Uterine cancer. In: Berek J.S., and Hacker N.F. (Eds). Practical Gynecologic Oncology (2005), Lippincott Williams and Wilkins, Baltimore 397-442
8. Ho D.M.T., Hsu C.Y., and Chiang H. MIB-1 labeling index as a prognostic indicator for survival in patients with FIGO stage IB squamous cell carcinoma of the cervix. Gynecol. Oncol. 76 (2000) 97-102
9. Ikeda K., Tate G., Suzuki T., and Mitsuya T. Effusion cytodiagnosis of carcinosarcoma derived from the female genital tract: immunohistochemical features of MMP-7 and Ki-67 and immunofluorescence double staining analyses of eight cases. Gynecol. Oncol. 97 (2005) 323-329
10. Inthasorn P., Carter J., Valmadre S., Beale P., Russell P., and Dalrymple C. Analysis of clinicopathologic factors in malignant mixed Mullerian tumors of the uterine corpus. Int. J. Gynecol. Cancer 12 (2002) 348-353
11. Iwasa Y., Haga H., Konishi I., Kobashi Y., Higuchi K., Katsuyama E., Minamiguchi S., and Yamabe H. Prognostic factors in uterine carcinosarcoma: a clinicopathologic study of 25 patients. Cancer 82 (1998) 512-519
12. Jeczen R., Skomra D., Cybulski M., Schneider-Stock R., Szewczuk W., Roessner A., Rechberger T., and Semczuk A. P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome. Clin. Exp. Metastasis 24 (2007) 503-511
13. Jin Z., Ogata S., Tamura G., Katayama Y., Fukase M., Yajima M., and Motoyama T. Carcinosarcomas (malignant Mullerian mixed tumors) of the uterus and ovary: a genetic study with special reference to histogenesis. Int. J. Gynecol. Pathol. 22 (2003) 368-373
14. Kounelis S., Jones M.W., Papadaki H., Bakker A., Swalsky P., and Finkelstein S.D. Carcinosarcomas (malignant mixed Mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components. Hum. Pathol. 29 (1998) 82-87
15. Kuroda N., Moriki T., Oguri H., Maeda N., Toi M., Miyazaki E., Hiroi M., Fukaya T., and Enzan H. Malignant Mullerian mixed tumor (carcinosarcoma) of the fallopian tube: an immunohistochemical study of neoplastic cells. APMIS 113 (2000) 643-646
16. Layfield L.J., Saria E.A., Berchuck A., Dodge R.K., Thompson J.K., Conlon D.H., and Kerns B.J. Prognostic value of MIB-1 in advanced ovarian carcinoma as determined using automated immunohistochemistry and quantitative image analysis. J. Surg. Oncol. 66 (1997) 230-236
17. Mayall F., Rutty K., Campbell F., and Goddard H. p53 immunostaining suggests that uterine carcinosarcomas are monoclonal. Histopathology 24 (1994) 211-214
18. McCluggage W.G. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas. Int. J. Gynecol. Cancer 12 (2002) 687-690
19. Nicotina P.A., Ferlazzo G., and Vincelli A.M. Proliferation indices and p53-immunocytochemistry in uterine mixed Mullerian tumors. Histol. Histopathol. 12 (1997) 967-972
20. Ronnett B.M., Zaino R.S., Ellenson L.H., and Kurman R.J. Endometrial carcinoma. In: Kurman R.J. (Ed). Blaustein's Pathology of the Female Genital Tract. fifth ed. (2002), Springer, New York, Berlin, Heidelberg 538-541
21. Salvesen H., Iversen O.E., and Akslen L.A. Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clin. Cancer Res. 4 (1998) 2779-2785
22. Semczuk A., Skomra D., Cybulski M., and Jakowicki J.A. Immunohistochemical analysis of MIB-1 proliferative activity in human endometrial cancer. Correlation with clinicopathological parameters, patient outcome, retinoblastoma immunoreactivity and K-ras codon 12 point mutations. Histochem. J. 33 (2001) 193-200
23. Semczuk A., Skomra D., Rybojad P., Jeczen R., and Rechberger T. Endometrial carcinoma with pleural metastasis: a case report. Acta Cytol. 50 (2006) 697-700
24. Shibata R., Umezawa A., Takehara K., Aoki D., Nozawa S., and Hata J. Primary carcinosarcoma of the vagina. Pathol. Int. 53 (2003) 106-110
25. Silverberg S.G., Major F.J., Blessing J.A., Fetter B., Askin F.B., Liao S.Y., and Miller A. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A gynecologic oncology group pathologic study of 203 cases. Int. J. Gynecol. Pathol. 9 (1990) 1-19
26. Wada H., Enomoto T., Fujita M., Yoshino K., Nakashima R., Kurachi H., Haba T., Wakasa K., Shroyer K.R., Tsujimoto M., Hongyo T., Nomura T., and Murata Y. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res. 57 (1997) 5379-5385
27. Watanabe M., Shimizu K., Kato H., Imai H., Nakano H., Sugawa M., and Shiraishi T. Carcinosarcoma of the uterus: immunohistochemical and genetic analysis of clonality of one case. Gynecol. Oncol. 82 (2001) 563-567
28. Yaziji H., and Gown A.M. Immunohistochemical analysis of gynecologic tumors. Int. J. Gynecol. Pathol. 20 (2001) 64-78